

Outcomes for PJI Treatment are Superior at Centers of Excellence

Akeem A. Williams, MBS; Alexander Hoffman, MD; Nicholas P. Drain, MD; Jamie Heimroth, MD; Kenneth Urish MD, PhD; Michael J. O'Malley, MD; Brian A. Klatt, MD; and Johannes F. Plate MD, PhD

Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh



Faculty Disclosure Information

Authors have no relevant disclosures







Background

- Periprosthetic joint infection (PJI) is the leading cause of total joint arthroplasty (TJA) failure.
- Centers of Excellence (COE) with fellowship-trained arthroplasty surgeons offer specialized care.
- This study compares outcomes between COE and Non-COE hospitals within the same healthcare system.







Methods

- A retrospective cohort study between 2016-2024 was conducted using data from 504 patients treated at COE and 390 patients treated at Non-COE* for total hip and knee PJI.
- The COE group comprises three hospitals, while the Non-COE group includes thirteen hospitals within the same healthcare system.
- We analyzed demographic variables, complications, readmissions, discharge dispositions, and patient-reported outcomes.
- Statistical analyses, including chi-square tests and T-tests, were used to compare proportions and mean values between the two groups.








COE classification

- 3 Hospitals with highest percentage of revisions are classified as COEs
- These hospitals also have fellowship trained arthroplasty surgeons









Results: Demographic Information

	COE (n=504)	NCOE (n=390)	<i>P</i> -value
Age (mean)	66	67	0.31
BMI (mean)	36.9	37.3	0.50
White (N(%))	474 (94.0)	370 (94.8)	0.900
Black (N(%))	23 (4.5)	16 (4.1)	0.743
Female (N(%))	233 (46.2)	181 (48.9)	0.50
THA (N(%))	235 (46.6)	162 (41.5)	0.147
TKA (N(%))	267 (53)	228 (58.5)	0.117
Risk of Mortality Score	1.63	1.86	0.001*
Severity of Illness Score	2.16	2.40	0.001*







Results: Complications at COE vs

Post-operative Complications	COE (504) N (%)	NCOE (390) N (%)	P-value
90 Day Any Complication	112 (22.2)	116 (29.7)	0.027*
90 Day Myocardial Infarction	1 (0.2)	0 (0.0)	0.37
90 Day Mechanical Complication	33 (6.5)	13 (3.3)	0.033*
90 Day Pulmonary Embolism	6 (1.2)	5 (1.3)	0.90
90 Day Pneumonia	3 (0.6)	5 (1.3)	0.28
90 Day Sepsis	52 (10.3)	71 (18.2)	<.001*
90 Day Wound Infection	34 (6.8)	37 (9.5)	0.13
90 Day Surgical Site Bleed	0 (0.0)	1 (0.3)	0.25
90 Day Surgical Site Infection	10 (2.0)	13 (3.3)	0.21
30 Day Mortality	2 (0.4)	4 (1.0)	0.25
90 Day Mortality	3 (0.6)	7 (1.8)	0.09
1 Year Mortality	23 (4.6)	19 (4.9)	0.82
1 Year Unplanned Revision	123 (24.4)	94 (24.1)	0.98
7 Day Readmission	20 (4.0)	16 (4.1)	0.91
30 Day Readmission	68 (13.5)	53 (13.6)	0.96
90 Day Readmission	112 (22.2)	91 (23.3)	0.69


The comparison of postoperative complications between groups showed a significantly lower overall all-cause NQF 1550 complication rate (22.2 versus 29.7%; P = 0.027) and sepsis (10.3 versus 8.2%; P < 0.001 in the COE.





Conclusion

- Using a volume-based definition of COE, we demonstrate that high-volume COEs are associated with reduced complications following revision total joint arthroplasty.
- The study highlights the importance of specialized regional centers in managing complex PJI cases.
- Further research is necessary to better understand this trend







Citations

[1] Badawy M, Espehaug B, Indrekvam K, Engesæter LB, Havelin LI, Furnes O. Influence of Hospital Volume on Revision Rate After Total Knee Arthroplasty with Cement. Journal of Bone and Joint Surgery 2013;95:e131. https://doi.org/10.2106/JBJS.L.00943.

[2] Grayson CW, Decker RC. Total joint arthroplasty for persons with osteoarthritis. PM R 2012;4:S97-103. https://doi.org/10.1016/j.pmrj.2012.02.018.

[3] Mehrotra A, Sloss EM, Hussey PS, Adams JL, Lovejoy S, Soohoo NF. Evaluation of Centers of Excellence program for knee and hip replacement. Med Care 2013;51:28–36. https://doi.org/10.1097/MLR.0b013e3182699407.

[4] Reeves RA, Schairer WW, Jevsevar DS. Costs and Risk Factors for Hospital Readmission After Periprosthetic Knee Fractures in the United States. J Arthroplasty 2018;33:324-330.e1. https://doi.org/10.1016/j.arth.2017.09.024.

